TEK and pancreatic neoplasm: The Ang2–Tie2 pathway has also been targeted with a monoclonal antibody blocking the Ang2–Tie2 interaction in TEMs, reducing angiogenesis but increasing the recruitment of macrophages in murine breast and pancreatic cancer models [131].